Abstract
Obesity is one of the major health problems of the modern era. Obesity has been associated with rapidly rising growth rates that affect every age group of the population indiscriminately, particularly the younger ones. Undoubtedly, it is necessary to identify increasingly effective therapies in order to avoid the possible complications of the syndrome. In this context, the microbiota can represent one of the therapeutic targets for the prevention and treatment of obesity. We highlight the role of the microbiota as a therapeutic target in obesity.
Keywords: Health, obesity, dysbiosis, pathogenesis, treatment, metabolism.
Graphical Abstract
[1]
Avolio, E.; Gualtieri, P.; Romano, L.; Pecorella, C.; Ferraro, S.; Palma, G.; Di Renzo, L.; De Lorenzo, A. Obesity and body composition in man and woman: Associated diseases and the new role of gut microbiota. Curr. Med. Chem., 2020, 27(2), 216-229.
[http://dx.doi.org/10.2174/0929867326666190326113607] [PMID: 30914014]
[http://dx.doi.org/10.2174/0929867326666190326113607] [PMID: 30914014]
[2]
Apovian, C.M. Obesity: Definition, comorbidities, causes, and burden. Am. J. Manag. Care, 2016, 22(7)(Suppl.), s176-s185.
[PMID: 27356115]
[PMID: 27356115]
[3]
Abenavoli, L.; Scarpellini, E.; Colica, C.; Boccuto, L.; Salehi, B.; Sharifi-Rad, J.; Aiello, V.; Romano, B.; De Lorenzo, A.; Izzo, A.A.; Capasso, R. Gut microbiota and obesity: A role for probiotics. Nutrients, 2019, 11(11), 2690.
[http://dx.doi.org/10.3390/nu11112690] [PMID: 31703257]
[http://dx.doi.org/10.3390/nu11112690] [PMID: 31703257]
[4]
Abenavoli, L.; Procopio, A.C.; Scarpellini, E.; Polimeni, N.; Aquila, I.; Larussa, T.; Boccuto, L.; Luzza, F. Gut microbiota and non-alcoholic fatty liver disease: A narrative review. Rev. Recent Clin. Trials, 2021. Online ahead of print
[http://dx.doi.org/10.23736/S2724-5985.21.02896-5] [PMID: 33871224]
[http://dx.doi.org/10.23736/S2724-5985.21.02896-5] [PMID: 33871224]
[5]
Abenavoli, L.; Larussa, T.; Corea, A.; Procopio, A.C.; Boccuto, L.; Dallio, M.; Federico, A.; Luzza, F. Dietary polyphenols and non-alcoholic fatty liver disease. Nutrients, 2021, 13(2), 494.
[http://dx.doi.org/10.3390/nu13020494] [PMID: 33546130]
[http://dx.doi.org/10.3390/nu13020494] [PMID: 33546130]
[6]
Scarpellini, E.; Cazzato, A.; Lauritano, C.; Gabrielli, M.; Lupascu, A.; Gerardino, L.; Abenavoli, L.; Petruzzellis, C.; Gasbarrini, G.; Gasbarrini, A. Probiotics: Which and when? Dig. Dis., 2008, 26(2), 175-182.
[http://dx.doi.org/10.1159/000116776] [PMID: 18431068]
[http://dx.doi.org/10.1159/000116776] [PMID: 18431068]
[7]
Méndez-Sánchez, N.; Valencia-Rodríguez, A.; Vera-Barajas, A.; Abenavoli, L.; Scarpellini, E.; Ponciano-Rodríguez, G.; Wang, D.Q.H. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. Hepatoma Res., 2020, 6, 5.
[http://dx.doi.org/10.20517/2394-5079.2019.29] [PMID: 32582865]
[http://dx.doi.org/10.20517/2394-5079.2019.29] [PMID: 32582865]
[8]
Moldovan, D.C.; Ismaiel, A.; Fagoonee, S.; Pellicano, R.; Abenavoli, L.; Dumitrascu, D.L. Gut microbiota and cardiovascular diseases axis: A review. Minerva Med., 2021. Online ahead of print
[http://dx.doi.org/10.23736/S0026-4806.21.07527-3] [PMID: 33969961]
[http://dx.doi.org/10.23736/S0026-4806.21.07527-3] [PMID: 33969961]
[9]
Dao, M.C.; Everard, A.; Aron-Wisnewsky, J.; Sokolovska, N.; Prifti, E.; Verger, E.O.; Kayser, B.D.; Levenez, F.; Chilloux, J.; Hoyles, L.; Dumas, M.E.; Rizkalla, S.W.; Doré, J.; Cani, P.D.; Clément, K. Akkermansia muciniphila and improved metabolic health during a dietary intervention in obesity: Relationship with gut microbiome richness and ecology. Gut, 2016, 65(3), 426-436.
[http://dx.doi.org/10.1136/gutjnl-2014-308778] [PMID: 26100928]
[http://dx.doi.org/10.1136/gutjnl-2014-308778] [PMID: 26100928]
[10]
Depommier, C.; Everard, A.; Druart, C.; Plovier, H.; Van Hul, M.; Vieira-Silva, S.; Falony, G.; Raes, J.; Maiter, D.; Delzenne, N.M.; de Barsy, M.; Loumaye, A.; Hermans, M.P.; Thissen, J.P.; de Vos, W.M.; Cani, P.D. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: A proof-of-concept exploratory study. Nat. Med., 2019, 25(7), 1096-1103.
[http://dx.doi.org/10.1038/s41591-019-0495-2] [PMID: 31263284]
[http://dx.doi.org/10.1038/s41591-019-0495-2] [PMID: 31263284]
[11]
Armougom, F.; Henry, M.; Vialettes, B.; Raccah, D.; Raoult, D. Monitoring bacterial community of human gut microbiota reveals an increase in Lactobacillus in obese patients and Methanogens in anorexic patients. PLoS One, 2009, 4(9), e7125.
[http://dx.doi.org/10.1371/journal.pone.0007125] [PMID: 19774074]
[http://dx.doi.org/10.1371/journal.pone.0007125] [PMID: 19774074]
[12]
Santacruz, A.; Collado, M.C.; García-Valdés, L.; Segura, M.T.; Martín-Lagos, J.A.; Anjos, T.; Martí-Romero, M.; Lopez, R.M.; Florido, J.; Campoy, C.; Sanz, Y. Gut microbiota composition is associated with body weight, weight gain and biochemical parameters in pregnant women. Br. J. Nutr., 2010, 104(1), 83-92.
[http://dx.doi.org/10.1017/S0007114510000176] [PMID: 20205964]
[http://dx.doi.org/10.1017/S0007114510000176] [PMID: 20205964]
[13]
Schwiertz, A.; Taras, D.; Schäfer, K.; Beijer, S.; Bos, N.A.; Donus, C.; Hardt, P.D. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring), 2010, 18(1), 190-195.
[http://dx.doi.org/10.1038/oby.2009.167] [PMID: 19498350]
[http://dx.doi.org/10.1038/oby.2009.167] [PMID: 19498350]
[14]
Kobyliak, N.; Abenavoli, L.; Falalyeyeva, T.; Beregova, T. Efficacy of probiotics and smectite in rats with non-alcoholic fatty liver disease. Ann. Hepatol., 2018, 17(1), 153-161.
[http://dx.doi.org/10.5604/01.3001.0010.7547] [PMID: 29311399]
[http://dx.doi.org/10.5604/01.3001.0010.7547] [PMID: 29311399]
[15]
Schütz, F.; Figueiredo-Braga, M.; Barata, P.; Cruz-Martins, N. Obesity and gut microbiome: Review of potential role of probiotics. Porto Biomed. J., 2021, 6(1), e111.
[http://dx.doi.org/10.1097/j.pbj.0000000000000111] [PMID: 33490703]
[http://dx.doi.org/10.1097/j.pbj.0000000000000111] [PMID: 33490703]
Article Metrics
5